Johnson & Johnson Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.7%projected annual EPS growth
Analyst Coverage
22analysts covering
FY Revenue (est.)
$101.1Bnext fiscal year
FY EPS (est.)
$11.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 2026 Earnings Release | 21 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Innovative Medicine Segment Operational Sales Growth Quarterly740.0%Target: 5% to 7% operational sales CAGR through 2030
MedTech Segment Operational Sales Growth Quarterly770.0%Target: Accelerated growth backed by new product platforms
Adjusted Pretax Operating Margin Improvement AnnuallyTarget: Improvement of at least 50 basis points in 2026
Watch Items
- STELARA Biosimilar Competition ImpactTrigger: Erosion exceeding the assumed $3 billion decline in 2026Action: Accelerate commercial launches of Tremfya and Icotyde to offset immunology segment headwinds.
- Ongoing Talc Litigation ExposureTrigger: Over 67,000 pending lawsuits and potential adverse jury awardsAction: Monitor settlement progress, legal reserve allocations, and bankruptcy-related restructuring strategies.
- DePuy Synthes Orthopaedics SpinoffTrigger: Execution timeline targeted for late 2026Action: Evaluate transaction structure, tax implications, and post-spinoff growth profile of the remaining MedTech business.
Research as of 2 Sep 2026